Ibrutinib

跨国药企正进入中报季，集中展现其在全球市场的布局与战略调整。7月17日，诺华发布2025年半年报：创造净销售额为272.87亿美元，按固定汇率计算同比增长13%（下同）；实现净利润为76.33亿美元，同比增长31%。其中，诺华中国区销售额为22亿美元，同比增长8%。无独有偶，强生也在前一天发布2025年半年报：其创新制药和医疗科技两大核心业务板块共同创造了高达456.36亿美元的营收，同比增长4.1%。其中，创新制药板块为强生带来290.75亿美元的收入，同比增长3.6%。在日益复杂的国际医药环境中，跨国药企凭借强大的研发实力和多元化的产品线，持续推动创新药物的研发和市场拓展。同时，面对全球医药市场的变化，这些制药巨头也在不断优化业务结构，提升运营效率，以期在激烈的市场竞争中保持领先地位。MNC半年报的密集公布，为业界提供了一个宝贵的观察视角。 诺华：肿瘤药创收超80亿美元作为一家纯粹的创新药物公司，诺华明确专注于心血管-肾脏-代谢、免疫学、神经科学和肿瘤学四大核心治疗领域。具体来看，在上半年，肿瘤学管线为诺华贡献了最多收入，高达81.99亿美元，同比增长22%。其中，凭借将适应症范围扩展至早期乳腺癌患者，诺华的明星抗癌药CDK4/6抑制剂Kisqali（瑞波西利）在上半年实现了强劲增长，创造了21.33亿美元，同比增长高达60%。Kisqali上半年居于诺华Top20畅销药榜单的第三位，增速仅次于心血管-肾脏-代谢管线的长效PCSK9产品Leqvio（英克司兰），全年销售额或将突破40亿美元。 诺华两款核药Pluvicto（镥[177Lu]特昔维匹肽）和Lutathera（镥[177lu]氧奥曲肽）同样表现不俗，共同创造了12.25亿美元营收。其中，Pluvicto在2024年销售额首次突破10亿美元大关，成为诺华旗下又一款“重磅炸弹”药物，其针对前列腺癌的两项适应症已在国内提交上市申请。心血管-肾脏-代谢管线的贡献仅次于肿瘤学，上半年为诺华创造了51.73亿美元收入，同比增长26%。其中，兼具降压和抗心力衰竭作用的重磅药物Entresto（沙库巴曲缬沙坦）仍是诺华的支柱产品，46.18亿美元销售额和同比22%的强劲增长令其继续霸榜诺华全球最畅销产品。值得一提的是，Entresto尽管在第十一批国采中因存在专利侵权高风险而被豁免纳入，但已有南京一心和、科伦药业两家国内企业的同品种药物突破专利壁垒上市。不仅如此，Entresto在美国市场的独占期也正在受到来自MSN制药、瑞迪博士等公司的多款仿制药挑战。与此同时，该药在美国的Medicare谈判将在明年执行，为其市场表现再添变数。销售增速最高的Leqvio同样值得期待，其在上半年实现收入5.55亿美元，同比增加66%，加速向“重磅炸弹”药物行列迈进。未来若治疗青少年高胆固醇血症等适应症获批，Leqvio有望接棒Entresto，成为诺华的新支柱产品。在免疫学领域，诺华实现收入49.58亿美元，同比增长13%。其中，明星产品Cosentyx（司库奇尤单抗）增速有所放缓，上半年实现收入31.63亿美元，同比增长11%。在中国，Cosentyx的核心专利即将到期，百奥泰已在今年2月提交司库奇尤单抗生物类似药上市申请，市场竞争一触即发。在神经领域，诺华创造收入27.59亿美元，同比增长23%。Kesimpta（奥法妥木单抗）凭借居家注射的便利性，销售额同比增速已提至38%，迅速打开多发性硬化症市场，为诺华在报告期内创收19.76亿美元。基于目前的业绩表现，诺华展望，如果未发生不可预见事件，其全年净销售额将实现高个位数增长。强生：传奇CAR-T实现翻倍增长强生与诺华深耕的疾病领域部分重合，强生聚焦肿瘤、自身免疫、神经科学、感染、肺动脉高压、心血管及代谢等关键领域。其中，肿瘤板块仍是强生创新制药业务的重中之重。上半年，肿瘤板块为强生取得了119.90亿美元的营收，同比增长21.1%。具体来看，该板块主要增长依然来源于Darzalex（达雷妥尤单抗）、Carvykti（西达基奥仑赛）、Erleada（阿帕他胺）和Rybrevant/Lazcluze（埃万妥单抗/兰泽替尼）等拳头产品。 作为全球首个获批上市的CD38单抗，Darzalex已成为全球多发性骨髓瘤临床治疗的核心产品，上半年创收67.76亿美元，同比增长21.7%，独自撑起了强生肿瘤板块销售额的“半壁江山”，再度超出业界预期。为了巩固自身在多发性骨髓瘤的霸主地位，强生推出更丰富的产品矩阵，其和传奇生物共同开发的CAR-T细胞疗法Carvykti尤为亮眼。上半年，Carvykti的销售额高达8.08亿美元，同比增长136%，朝着全球年销售额20亿美元的目标狂飙。但英雄迟暮，强生昔日的血液瘤重磅产品Imbruvica（伊布替尼）因同类药物竞争，销售额同比下降7.0%，仅剩14.44亿美元。不过，强生的双抗药物管线正加快显现在多发性骨髓瘤治疗领域的价值。全球首款CD3/BCMA双抗Tecvayli（特立妥单抗）上半年实现销售额3.17亿美元，同比增长18.2%；GPRC5D/CD3双抗Talvey（塔奎妥单抗）也加快放量，实现销售额1.92亿美元，同比增长52%。今年2月，Talvey已在中国获批，用于治疗复发或难治性多发性骨髓瘤。除了血液肿瘤，强生在实体瘤领域也逐步站稳脚跟。其中，雄激素受体抑制剂Erleada（阿帕他胺）是强生在前列腺癌领域的核心产品，上半年创收16.79亿美元，同比增长17.8%。不仅如此，非小细胞肺癌产品组合EGFR/c-Met双抗Rybrevant（埃万妥单抗）和EGFR T790M抑制剂Lazcluze（兰泽替尼）已成功进击一线治疗场景，上半年合计带来3.20亿美元的收入。在过去引以为傲的自免领域，强生正面临前所未有的挑战，该板块在报告期内实现77.00亿美元收入，同比下滑14.1%。具体来看，强生的核心自免产品IL-12p40单抗Stelara（乌司奴单抗）受到生物类似药的强烈冲击，收入仅为32.78亿美元，同比下降38.6%。 在克罗恩病新适应症的加持下，强生的IL-23p19单抗Tremfya（古塞奇尤单抗）继续保持25%的高增长，上半年销售额为21.42亿美元。但独木难支，Tremfya的市场增量也难以抵消Stelara、Remicade（英夫利西单抗）和Simponi（戈利木单抗）等专利过期药的销售额下滑。为挽颓势，强生加快培育自免领域的“新接班人”。今年4月，强生65亿美元收购押注的FcRn阻断剂Imaavy（nipocalimab）获得FDA批准上市，用于治疗重症肌无力。此外，口服IL-23R拮抗剂icotrokinra的两项斑块状银屑病Ⅲ期研究已经取得成功，距离上市只差临门一脚。强生判断，当前的产品组合和研发管线使其有望在今年下半年实现高速增长，预计将在肺癌和膀胱癌、重度抑郁症、牛皮癣和心血管等领域获得突破性的批准和提交申请，将以变革性方式改善患者获益。编辑：范晓艳版式编辑：于成林审校：马飞、张松医保飞检来袭！医院、药店这些领域将被重点核查五年3次100亿美元大并购！默沙东将在何处培育“新药王”？第十一批国采正式启动！55个品种入围，涉及默沙东、AZ、诺华、正大天晴、齐鲁、石药www.yyjjb.com.cn洞悉行业趋势 长按关注医药经济报  《中国处方药》学术公众号聚焦药学学术和循证研究   长按关注中国处方药    《医药经济报》终端公众号记录药品终端产经大事件 长按关注21世纪药店

2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* 2025 Second-Quarter reflects earnings per share (EPS) of $2.29 and adjusted EPS of $2.77 Significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA Strong operational performance and favorable foreign exchange results in Company increasing full year estimated reported sales5 guidance at the midpoint by $2 billion dollars to 5.4% and full year EPS guidance by $0.25 to $10.85. Adjusted operational EPS increased to $10.68 at the midpoint. NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. “Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business operating across both MedTech and Innovative Medicine,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery and cardiovascular, which will extend and improve lives in transformative ways.” Overall financial results Q2 ($ in Millions, except EPS) 2025 2024 % Change Reported Sales $23,743 $22,447 5.8% Net Earnings $5,537 $4,686 18.2% EPS (diluted) $2.29 $1.93 18.7% Q2 Non-GAAP* ($ in Millions, except EPS) 2025 2024 % Change Operational Sales1,2 4.6% Adjusted Operational Sales1,3 3.0% Adjusted Net Earnings1,4 $6,699 $6,840 -2.1% Adjusted EPS (diluted)1,4 $2.77 $2.82 -1.8% Free Cash Flow6,7 ~$6,200 $7,507 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine 6 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. 7 Second-quarter YTD 2025 is estimated as of July 16, 2025 Regional sales results Q2 % Change ($ in Millions) 2025 2024 Reported Operational1,2 Currency Adjusted Operational1,3 U.S. $13,544 $12,569 7.8% 7.8 - 5.0 International 10,199 9,878 3.2 0.6 2.6 0.4 Worldwide $23,743 $22,447 5.8% 4.6 1.2 3.0 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Segment sales results Q2 % Change ($ in Millions) 2025 2024 Reported Operational1,2 Currency Adjusted Operational1,3 Innovative Medicine $15,202 $14,490 4.9% 3.8 1.1 2.4 MedTech 8,541 7,957 7.3 6.1 1.2 4.1 Worldwide $23,743 $22,447 5.8% 4.6 1.2 3.0 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Second-Quarter 2025 segment commentary: Operational sales* reflected below excludes the impact of translational currency. Innovative Medicine Innovative Medicine worldwide operational sales grew 3.8%*, with net acquisitions and divestitures positively impacting growth by 1.4%. Growth was primarily driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience. Growth was partially offset by an approximate (1,170) basis points impact from STELARA in Immunology, and an approximate (130) basis points impact from COVID-19 in Infectious Diseases. MedTech MedTech worldwide operational sales grew 6.1%*, with net acquisitions and divestitures positively impacting growth by 2.0%. Growth was primarily driven by electrophysiology products and Abiomed in Cardiovascular, as well as wound closure products in General Surgery. Full-year 2025 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. ($ in Billions, except EPS) July 2025 April 2025 Adjusted Operational Sales1,2,5 Change vs. Prior Year / Mid-point 3.2% – 3.7% / 3.5% 2.0% – 3.0% / 2.5% Operational Sales2,5 / Mid-point Change vs. Prior Year / Mid-point $92.7B – $93.1B / $92.9B 4.5% – 5.0% / 4.8% $91.6B – $92.4B / $92.0B 3.3% – 4.3% / 3.8% Estimated Reported Sales3,5/ Mid-point Change vs. Prior Year / Mid-point $93.2B – $93.6B / $93.4B 5.1% – 5.6% / 5.4% $91.0B – $91.8B / $91.4B 2.6% – 3.6% / 3.1% Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point $10.63 – $10.73 / $10.68 6.5% – 7.5% / 7.0% $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% Adjusted EPS (Diluted)3,4 / Mid-point Change vs. Prior Year / Mid-point $10.80 – $10.90 / $10.85 8.2% – 9.2% / 8.7% $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: July 2025 = $1.13 and April 2025 = $1.10 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine Other modeling considerations will be provided on the webcast Notable announcements in the quarter: The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at News Releases, as well as Innovative Medicine News Center, MedTech News & Events, and www.factsabouttalc.com. Regulatory Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo1 Press Release DARZALEX® (daratumumab) receives the first positive CHMP opinion for patients with high-risk smouldering multiple myeloma Press Release IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant Press Release U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma Press Release Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG) Press Release Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA™ Robotic Surgical System Press Release Data Releases IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC) Press Release Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease Press Release Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma Press Release New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia Press Release Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison Press Release New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis Press Release DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity Press Release Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients Press Release Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma Press Release Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC Press Release Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer Press Release Shockwave Medical Study Confirms Benefit of IVL-First Strategy in Real-World Female Patients with Complex Calcified Lesions in Late-Breaking Data Presentation at EuroPCR 2025 Press Release Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis Press Release TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years Press Release TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks Press Release Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC Press Release Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer Press Release Johnson & Johnson MedTech Presents 3-Month Data from Omny-IRE Clinical Trial at 2025 Heart Rhythm Society Annual Meeting Press Release Product Launch Johnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM Press Release Johnson & Johnson Launches VOLT™ Wrist and Proximal Humerus Plating Systems in the U.S. Press Release Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens in Europe, the Middle East, and Canada Offering Cataract Patients Precise Vision at Every Distance in Any Lighting Press Release Johnson & Johnson Launches KINCISE™ 2 System, the Only Automated Surgical Impactor Approved for Knee and Hip Revision Procedures Press Release Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL™ in the US, Redefining Image Clarity in 2D Intracardiac Imaging Press Release Other Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors Press Release 1 Subsequent to the quarter Webcast information: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations. About Johnson & Johnson: At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com. Non-GAAP financial measures: * “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results. Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results. Note to investors concerning forward-looking statements: This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Percent Change Percent Change 2025 2024 Total Operations Currency 2025 2024 Total Operations Currency $ 9,161 8,510 7.6 % 7.6 - $ 17,253 16,122 7.0 % 7.0 - 6,041 5,980 1.0 (1.6 ) 2.6 11,822 11,930 (0.9 ) (0.1 ) (0.8 ) 15,202 14,490 4.9 3.8 1.1 29,075 28,052 3.6 4.0 (0.4 ) 4,383 4,059 8.0 8.0 - 8,596 8,067 6.6 6.6 - 4,158 3,898 6.7 4.1 2.6 7,965 7,711 3.3 3.6 (0.3 ) 8,541 7,957 7.3 6.1 1.2 16,561 15,778 5.0 5.1 (0.1 ) 13,544 12,569 7.8 7.8 - 25,849 24,189 6.9 6.9 - 10,199 9,878 3.2 0.6 2.6 19,787 19,641 0.7 1.4 (0.7 ) $ 23,743 22,447 5.8 % 4.6 1.2 $ 45,636 43,830 4.1 % 4.4 (0.3 ) Percent Change Percent Change 2025 2024 Total Operations Currency 2025 2024 Total Operations Currency $ 13,544 12,569 7.8 % 7.8 - $ 25,849 24,189 6.9 % 6.9 - 5,387 5,214 3.3 (1.9 ) 5.2 10,497 10,377 1.1 0.2 0.9 1,206 1,212 (0.5 ) 6.2 (6.7 ) 2,373 2,406 (1.3 ) 7.7 (9.0 ) 3,606 3,452 4.4 2.4 2.0 6,917 6,858 0.9 0.9 0.0 10,199 9,878 3.2 0.6 2.6 19,787 19,641 0.7 1.4 (0.7 ) $ 23,743 22,447 5.8 % 4.6 1.2 $ 45,636 43,830 4.1 % 4.4 (0.3 ) 2025 2024 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) $ 23,743 100.0 $ 22,447 100.0 5.8 7,628 32.1 6,869 30.6 11.0 16,115 67.9 15,578 69.4 3.4 5,889 24.8 5,681 25.3 3.7 3,516 14.8 3,440 15.3 2.2 - - 194 0.9 48 0.2 (125 ) (0.6 ) 107 0.5 653 2.9 64 0.3 (13 ) 0.0 6,491 27.3 5,748 25.6 12.9 954 4.0 1,062 4.7 (10.2 ) $ 5,537 23.3 $ 4,686 20.9 18.2 $ 2.29 $ 1.93 18.7 2,419.1 2,422.0 14.7 % 18.5 % $ 8,188 34.5 $ 8,404 37.4 (2.6 ) $ 6,699 28.2 $ 6,840 30.5 (2.1 ) $ 2.77 $ 2.82 (1.8 ) 18.2 % 18.6 % 2025 2024 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) $ 45,636 100.0 $ 43,830 100.0 4.1 14,985 32.8 13,380 30.5 12.0 30,651 67.2 30,450 69.5 0.7 11,001 24.1 10,938 25.0 0.6 6,741 14.8 6,982 16.0 (3.5 ) - - 194 0.4 (80 ) (0.2 ) (334 ) (0.8 ) (7,214 ) (15.8 ) 3,057 7.0 81 0.2 151 0.3 20,122 44.1 9,462 21.6 112.7 3,586 7.9 1,521 3.5 135.8 $ 16,536 36.2 $ 7,941 18.1 108.2 $ 6.82 $ 3.27 108.6 2,423.3 2,428.5 17.8 % 16.1 % $ 16,199 35.5 $ 16,281 37.1 (0.5 ) $ 13,405 29.4 $ 13,420 30.6 (0.1 ) $ 5.53 $ 5.53 0.0 17.2 % 17.6 % 2025 2024 2025 2024 $5,537 $4,686 $16,536 $7,941 57 352 (6,909) 3,078 1,267 1,106 2,387 2,184 - 64 - 73 79 (11) 134 160 - 68 - 119 246 452 378 600 21 431 60 411 - 194 - 194 27 - 27 - (321) (437) 994 (1,293) (214) (65) (202) (47) $6,699 $6,840 $13,405 $13,420 2,419.1 2,422.0 2,423.3 2,428.5 $2.77 $2.82 $5.53 $5.53 $2.71 $5.52 1 2 4.9% 7.3% 5.8% 7.6% 8.0% 7.8% 1.0% 6.7% 3.2% 1.1 1.2 1.2 - - - 2.6 2.6 2.6 3.8% 6.1% 4.6% 7.6% 8.0% 7.8% (1.6)% 4.1% 0.6% (2.2) (0.8) (3.5) (1.1) (0.9) (0.3) (1.4) (0.9) (2.4) (1.7) 0.0 0.0 0.0 0.2 0.1 0.0 0.2 0.0 0.0 0.2 0.1 2.4% 4.1% 3.0% 5.2% 4.7% 5.0% (1.6)% 3.4% 0.4% Innovative Medicine MedTech Total 3.6% 5.0% 4.1% 7.0% 6.6% 6.9% (0.9)% 3.3% 0.7% (0.4) (0.1) (0.3) - - - (0.8) (0.3) (0.7) 4.0% 5.1% 4.4% 7.0% 6.6% 6.9% (0.1)% 3.6% 1.4% (2.7) (1.0) (4.3) (1.5) (1.1) (0.5) (0.8) (0.5) (1.3) (0.9) 0.0 0.0 0.1 0.3 0.2 0.0 0.5 0.2 0.2 0.2 0.2 3.3% 2.7% 3.1% 5.7% 2.8% 4.7% 0.1% 2.7% 1.1% REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS % Change % Change 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency $ 3,385 2,636 28.4 % 28.4 % - $ 6,398 5,019 27.5 % 27.5 % - 2,928 2,455 19.3 % 15.7 % 3.6 % 5,592 4,885 14.5 % 15.1 % -0.6 % 6,312 5,090 24.0 % 22.3 % 1.7 % 11,990 9,904 21.1 % 21.3 % -0.2 % 358 167 * * - 676 307 * * - 81 20 * * * 132 36 * * * 439 186 * * * 808 343 * * * 2,017 1,641 23.0 % 23.0 % - 3,846 3,105 23.9 % 23.9 % - 1,521 1,237 23.0 % 19.6 % 3.4 % 2,930 2,465 18.9 % 19.7 % -0.8 % 3,539 2,878 23.0 % 21.5 % 1.5 % 6,776 5,570 21.7 % 22.0 % -0.3 % 378 318 18.6 % 18.6 % - 670 603 11.0 % 11.0 % - 530 418 27.0 % 22.8 % 4.2 % 1,009 822 22.9 % 23.0 % -0.1 % 908 736 23.4 % 21.0 % 2.4 % 1,679 1,425 17.8 % 17.9 % -0.1 % 239 246 -2.7 % -2.7 % - 474 511 -7.3 % -7.3 % - 496 525 -5.4 % -8.4 % 3.0 % 970 1,043 -6.9 % -6.3 % -0.6 % 735 770 -4.5 % -6.6 % 2.1 % 1,444 1,554 -7.0 % -6.6 % -0.4 % 139 52 * * - 252 88 * * - 41 17 * * * 69 28 * * * 179 69 * * * 320 116 * * * 82 59 38.0 % 38.0 % - 150 109 36.7 % 36.7 % - 24 9 * * * 42 17 * * * 106 69 55.0 % 54.3 % 0.7 % 192 127 52.0 % 52.4 % -0.4 % 114 104 8.2 % 8.2 % - 219 205 6.6 % 6.6 % - 52 30 74.8 % 72.0 % 2.8 % 98 63 56.0 % 58.4 % -2.4 % 166 135 23.1 % 22.4 % 0.7 % 317 268 18.2 % 18.7 % -0.5 % 6 11 -38.9 % -38.9 % - 13 20 -31.9 % -31.9 % - 139 154 -9.8 % -13.3 % 3.5 % 257 326 -21.1 % -21.3 % 0.2 % 145 165 -11.6 % -14.9 % 3.3 % 270 346 -21.7 % -21.9 % 0.2 % 50 37 36.9 % 36.9 % - 97 70 39.8 % 39.8 % - 42 45 -8.7 % -12.3 % 3.6 % 84 86 -2.5 % -1.8 % -0.7 % 93 83 11.7 % 9.7 % 2.0 % 182 156 16.4 % 16.8 % -0.4 % REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS % Change % Change 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency $ 2,505 2,978 -15.9 % -15.9 % - $ 4,701 5,431 -13.4 % -13.4 % - 1,489 1,744 -14.6 % -16.2 % 1.6 % 2,999 3,538 -15.2 % -13.8 % -1.4 % 3,993 4,722 -15.4 % -16.0 % 0.6 % 7,700 8,969 -14.1 % -13.6 % -0.5 % 283 231 22.5 % 22.5 % - 597 497 20.1 % 20.1 % - 34 35 -2.6 % -2.6 % - 44 62 -28.7 % -28.7 % - 138 127 8.6 % 8.8 % -0.2 % 281 268 4.8 % 7.7 % -2.9 % 455 393 15.9 % 15.9 % 0.0 % 922 827 11.5 % 12.4 % -0.9 % 305 267 14.0 % 14.0 % - 597 521 14.4 % 14.4 % - 387 270 43.1 % 40.8 % 2.3 % 753 569 32.2 % 35.0 % -2.8 % 690 537 28.6 % 27.5 % 1.1 % 1,349 1,091 23.7 % 25.1 % -1.4 % 1,078 1,855 -41.9 % -41.9 % - 2,059 3,251 -36.7 % -36.7 % - 575 1,030 -44.2 % -45.6 % 1.4 % 1,219 2,085 -41.5 % -40.6 % -0.9 % 1,653 2,885 -42.7 % -43.2 % 0.5 % 3,278 5,336 -38.6 % -38.2 % -0.4 % 796 589 35.2 % 35.2 % - 1,395 1,098 27.1 % 27.1 % - 391 317 23.2 % 20.5 % 2.7 % 747 616 21.2 % 22.4 % -1.2 % 1,186 906 31.0 % 30.1 % 0.9 % 2,142 1,714 25.0 % 25.4 % -0.4 % 8 2 * * - 9 2 * * - 0 0 - - - 0 0 - - - 8 2 * * - 9 2 * * - 1,377 1,102 24.9 % 24.9 % - 2,345 2,156 8.7 % 8.7 % - 674 679 -0.8 % -2.6 % 1.8 % 1,353 1,428 -5.2 % -4.1 % -1.1 % 2,051 1,782 15.1 % 14.4 % 0.7 % 3,698 3,585 3.2 % 3.6 % -0.4 % 211 - * * - 211 - * * - - - - - - - - - - - 211 - * * - 211 - * * - 24 34 -27.7 % -27.7 % - 62 75 -16.6 % -16.6 % - 139 129 7.5 % 7.0 % 0.5 % 249 265 -6.0 % -4.4 % -1.6 % 164 163 0.2 % -0.2 % 0.4 % 312 340 -8.3 % -7.1 % -1.2 % 732 784 -6.7 % -6.7 % - 1,357 1,549 -12.4 % -12.4 % - 260 269 -3.5 % -5.1 % 1.6 % 537 561 -4.2 % -3.1 % -1.1 % 992 1,054 -5.9 % -6.3 % 0.4 % 1,895 2,110 -10.2 % -9.9 % -0.3 % 366 226 61.1 % 61.1 % - 642 417 53.7 % 53.7 % - 50 44 12.8 % 11.0 % 1.8 % 93 78 18.1 % 20.1 % -2.0 % 414 271 53.3 % 53.0 % 0.3 % 734 496 48.1 % 48.4 % -0.3 % 45 57 -23.5 % -23.5 % - 73 115 -37.0 % -37.0 % - 226 237 -4.7 % -7.6 % 2.9 % 474 524 -9.5 % -8.8 % -0.7 % 270 294 -8.4 % -10.7 % 2.3 % 547 639 -14.4 % -13.9 % -0.5 % REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS % Change % Change 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency $ 799 743 7.6 % 7.6 % - $ 1,543 1,509 2.3 % 2.3 % - 314 296 5.8 % 2.8 % 3.0 % 595 579 2.6 % 3.0 % -0.4 % 1,113 1,039 7.1 % 6.2 % 0.9 % 2,138 2,088 2.4 % 2.5 % -0.1 % 403 376 6.9 % 6.9 % - 766 732 4.6 % 4.6 % - 180 171 5.4 % 2.1 % 3.3 % 339 340 -0.3 % -0.2 % -0.1 % 582 548 6.4 % 5.4 % 1.0 % 1,104 1,072 3.0 % 3.1 % -0.1 % 382 349 9.4 % 9.4 % - 747 741 0.8 % 0.8 % - 94 76 22.4 % 19.8 % 2.6 % 180 152 17.9 % 18.7 % -0.8 % 476 426 11.7 % 11.3 % 0.4 % 927 894 3.7 % 3.8 % -0.1 % 16 17 -12.4 % -12.4 % - 31 35 -12.6 % -12.6 % - 40 49 -18.5 % -21.3 % 2.8 % 77 88 -12.4 % -12.1 % -0.3 % 55 67 -16.9 % -19.0 % 2.1 % 107 123 -12.5 % -12.3 % -0.2 % 320 334 -4.3 % -4.3 % - 635 658 -3.6 % -3.6 % - 484 631 -23.4 % -26.8 % 3.4 % 971 1,128 -13.9 % -14.1 % 0.2 % 803 965 -16.8 % -19.0 % 2.2 % 1,605 1,786 -10.1 % -10.2 % 0.1 % 6 8 -25.4 % -25.4 % - 14 16 -13.6 % -13.6 % - 354 288 23.0 % 16.7 % 6.3 % 704 603 16.7 % 15.6 % 1.1 % 360 297 21.6 % 15.5 % 6.1 % 718 620 15.9 % 14.9 % 1.0 % 312 321 -3.0 % -3.0 % - 617 635 -2.9 % -2.9 % - 85 117 -27.0 % -29.4 % 2.4 % 183 221 -17.2 % -15.8 % -1.4 % 396 438 -9.4 % -10.0 % 0.6 % 799 856 -6.6 % -6.3 % -0.3 % 2 5 -51.8 % -51.8 % - 4 7 -37.4 % -37.4 % - 45 227 -80.5 % -80.6 % 0.1 % 84 304 -72.5 % -72.1 % -0.4 % 47 233 -79.8 % -79.9 % 0.1 % 88 311 -71.7 % -71.3 % -0.4 % 776 717 8.2 % 8.2 % - 1,631 1,348 21.0 % 21.0 % - 154 176 -12.3 % -13.2 % 0.9 % 312 373 -16.2 % -14.3 % -1.9 % 930 892 4.2 % 4.0 % 0.2 % 1,943 1,721 12.9 % 13.3 % -0.4 % 621 587 5.6 % 5.6 % - 1,311 1,105 18.6 % 18.6 % - - - - - - - - - - - 621 587 5.6 % 5.6 % - 1,311 1,105 18.6 % 18.6 % - 155 129 20.0 % 20.0 % - 320 243 31.6 % 31.6 % - 154 176 -12.3 % -13.2 % 0.9 % 312 373 -16.2 % -14.3 % -1.9 % 309 305 1.4 % 0.9 % 0.5 % 632 616 2.7 % 3.9 % -1.2 % 9,161 8,510 7.6 % 7.6 % - 17,253 16,122 7.0 % 7.0 % - 6,041 5,980 1.0 % -1.6 % 2.6 % 11,822 11,930 -0.9 % -0.1 % -0.8 % $ 15,202 14,490 4.9 % 3.8 % 1.1 % $ 29,075 28,052 3.6 % 4.0 % -0.4 % REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS % Change % Change 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency $ 1,364 1,119 21.9 % 21.9 % - $ 2,625 2,144 22.4 % 22.4 % - 948 753 25.9 % 22.9 % 3.0 % 1,790 1,534 16.7 % 16.7 % 0.0 % 2,313 1,873 23.5 % 22.3 % 1.2 % 4,416 3,679 20.0 % 20.0 % 0.0 % 741 705 5.1 % 5.1 % - 1,425 1,397 2.0 % 2.0 % - 728 618 17.8 % 15.2 % 2.6 % 1,366 1,270 7.6 % 7.8 % -0.2 % 1,468 1,323 11.0 % 9.8 % 1.2 % 2,791 2,667 4.7 % 4.7 % 0.0 % 360 309 16.6 % 16.6 % - 699 612 14.2 % 14.2 % - 89 72 25.0 % 18.4 % 6.6 % 170 139 22.4 % 20.9 % 1.5 % 448 379 18.2 % 16.9 % 1.3 % 868 750 15.7 % 15.5 % 0.2 % 233 77 * * - 439 77 * * - 58 0 * * * 110 0 * * * 292 77 * * * 550 77 * * - 31 29 5.4 % 5.4 % - 63 59 6.3 % 6.3 % - 72 64 13.4 % 11.6 % 1.8 % 144 126 14.2 % 14.5 % -0.3 % 104 93 10.8 % 9.7 % 1.1 % 207 185 11.7 % 11.8 % -0.1 % 1,420 1,422 -0.2 % -0.2 % - 2,804 2,870 -2.3 % -2.3 % - 885 890 -0.5 % -4.0 % 3.5 % 1,742 1,782 -2.2 % -2.4 % 0.2 % 2,305 2,312 -0.3 % -1.6 % 1.3 % 4,546 4,652 -2.3 % -2.3 % 0.0 % 271 265 2.1 % 2.1 % - 534 535 -0.2 % -0.2 % - 150 152 -1.0 % -4.3 % 3.3 % 296 304 -2.5 % -2.6 % 0.1 % 421 417 1.0 % -0.2 % 1.2 % 830 839 -1.1 % -1.1 % 0.0 % 226 230 -1.9 % -1.9 % - 457 472 -3.1 % -3.1 % - 164 163 0.0 % -2.9 % 2.9 % 322 323 -0.5 % -0.4 % -0.1 % 389 394 -1.1 % -2.3 % 1.2 % 778 795 -2.0 % -2.0 % 0.0 % 501 498 0.7 % 0.7 % - 1,003 1,002 0.1 % 0.1 % - 267 260 2.2 % -1.5 % 3.7 % 537 521 2.9 % 2.8 % 0.1 % 768 759 1.2 % -0.1 % 1.3 % 1,540 1,524 1.1 % 1.0 % 0.1 % 422 430 -1.7 % -1.7 % - 810 862 -6.0 % -6.0 % - 305 314 -2.7 % -6.4 % 3.7 % 588 634 -7.2 % -7.7 % 0.5 % 727 743 -2.1 % -3.7 % 1.6 % 1,398 1,495 -6.5 % -6.7 % 0.2 % REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS % Change % Change 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency $ 1,043 995 4.8 % 4.8 % - $ 2,045 1,982 3.2 % 3.2 % - 1,512 1,493 1.3 % -0.2 % 1.5 % 2,906 2,922 -0.5 % 0.3 % -0.8 % 2,555 2,488 2.7 % 1.8 % 0.9 % 4,951 4,904 1.0 % 1.5 % -0.5 % 477 466 2.2 % 2.2 % - 934 912 2.4 % 2.4 % - 687 675 1.9 % 0.2 % 1.7 % 1,303 1,316 -1.0 % -0.4 % -0.6 % 1,164 1,141 2.0 % 1.0 % 1.0 % 2,237 2,228 0.4 % 0.8 % -0.4 % 567 528 7.2 % 7.2 % - 1,111 1,070 3.8 % 3.8 % - 825 818 0.9 % -0.6 % 1.5 % 1,603 1,606 -0.1 % 0.8 % -0.9 % 1,391 1,346 3.3 % 2.5 % 0.8 % 2,714 2,676 1.4 % 2.0 % -0.6 % 557 523 6.5 % 6.5 % - 1,123 1,070 4.9 % 4.9 % - 813 763 6.5 % 3.4 % 3.1 % 1,526 1,473 3.6 % 3.7 % -0.1 % 1,369 1,285 6.5 % 4.6 % 1.9 % 2,648 2,543 4.1 % 4.2 % -0.1 % 429 409 4.8 % 4.8 % - 881 847 3.9 % 3.9 % - 536 509 5.4 % 1.4 % 4.0 % 1,003 981 2.3 % 1.9 % 0.4 % 965 918 5.1 % 2.9 % 2.2 % 1,884 1,828 3.1 % 2.8 % 0.3 % 128 113 12.6 % 12.6 % - 242 223 8.5 % 8.5 % - 277 254 8.8 % 7.3 % 1.5 % 523 492 6.2 % 7.2 % -1.0 % 403 367 9.9 % 8.9 % 1.0 % 764 715 6.9 % 7.6 % -0.7 % 4,383 4,059 8.0 % 8.0 % - 8,596 8,067 6.6 % 6.6 % - 4,158 3,898 6.7 % 4.1 % 2.6 % 7,965 7,711 3.3 % 3.6 % -0.3 % $ 8,541 7,957 7.3 % 6.1 % 1.2 % $ 16,561 15,778 5.0 % 5.1 % -0.1 % Second Quarter June 29, 2025 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related (Loss)/gain on securities Tax legislation and other tax related Other Second Quarter June 29, 2025 Non-GAAP $ 3,978 (785 ) (13 ) 3,180 2,789 2,789 2,869 2,869 14 69 (207 ) 8 (13 ) (129 ) 5,552 785 (69 ) - 220 (8 ) - 13 6,493 $ 3,638 (482 ) (15 ) 1 3,142 2,862 2,862 647 43 690 190 (83 ) (64 ) (53 ) (29 ) (14 ) (53 ) 1,204 482 83 79 9 29 - 14 1,900 $ 12 12 238 238 - - 15 (43 ) (17 ) (45 ) (265 ) - 43 - 17 - - - (205 ) $ 7,628 (1,267 ) (15 ) (12 ) 6,334 5,889 5,889 3,516 43 3,559 107 (57 ) (277 ) (21 ) (27 ) (275 ) - - 48 48 64 (64 ) - 6,491 1,267 57 79 246 21 - 27 8,188 954 222 9 13 72 5 214 - 1,489 5,537 1,045 48 66 174 16 (214 ) 27 6,699 $ 3,603 (694 ) (4 ) 2,905 2,665 2,665 2,722 (10 ) 2,712 41 (43 ) (194 ) 63 (1 ) (70 ) (50 ) (254 ) 5,459 694 43 194 (63 ) 1 70 - 64 - 6,462 $ 3,248 (412 ) (2 ) (50 ) (30 ) 2,754 2,671 (5 ) 2,666 718 (15 ) (33 ) 670 231 4 (50 ) (344 ) (22 ) (181 ) 1,089 412 (4 ) - 52 409 22 68 - - 2,048 $ 18 18 345 345 - - 437 (313 ) (42 ) (339 ) (257 ) (800 ) - 313 - - 42 339 - - - (106 ) $ 6,869 (1,106 ) (2 ) (50 ) (30 ) (4 ) 5,677 5,681 (5 ) 5,676 3,440 (15 ) (33 ) (10 ) 3,382 653 (352 ) (387 ) (431 ) (50 ) (567 ) 194 (194 ) - (125 ) (125 ) (13 ) 13 - 5,748 1,106 352 194 (11 ) 452 431 68 64 - 8,404 1,062 156 70 43 (6 ) 125 21 14 14 65 1,564 4,686 950 282 151 (5 ) 327 410 54 50 (65 ) 6,840 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions $ 7,998 (1,434 ) (13 ) 6,551 5,050 5,050 5,417 5,417 (152 ) 69 (227 ) (10 ) (13 ) (333 ) 10,762 1,434 (69 ) - 240 10 - 13 12,390 $ 6,964 (953 ) (23 ) (51 ) 5,937 5,518 5,518 1,324 37 1,361 130 (83 ) (111 ) (107 ) (50 ) (14 ) (235 ) 2,625 953 83 134 121 50 - 14 3,980 $ 23 23 433 433 - - (7,191 ) 6,923 (17 ) (285 ) 6,735 - (6,923 ) - 17 - - - (171 ) $ 14,985 (2,387 ) (23 ) (64 ) 12,511 11,001 11,001 6,741 37 6,778 (7,214 ) 6,909 (30 ) (351 ) (60 ) (27 ) (773 ) - - (80 ) (80 ) 81 (81 ) - 20,122 2,387 (6,909 ) 134 378 60 - 27 16,199 3,586 410 (1,544 ) 24 102 14 202 2,794 16,536 1,977 (5,365 ) 110 276 46 (202 ) 27 13,405 $ 6,973 (1,392 ) (6 ) 5,575 5,103 5,103 5,618 (17 ) 5,601 (70 ) (43 ) (194 ) (81 ) (48 ) (15 ) (50 ) (501 ) 10,428 1,392 43 194 81 48 15 - 73 - 12,274 $ 6,368 (792 ) (9 ) (50 ) (50 ) 5,467 5,253 (9 ) 5,244 1,364 (33 ) (60 ) 1,271 184 4 (70 ) (387 ) (44 ) (313 ) 2,609 792 (4 ) - 79 470 44 119 - - 4,109 $ 39 39 582 582 - - 2,954 (3,039 ) (82 ) (352 ) (519 ) (3,575 ) - 3,039 - - 82 352 - - - (102 ) $ 13,380 (2,184 ) (9 ) (50 ) (50 ) (6 ) 11,081 10,938 (9 ) 10,929 6,982 (33 ) (60 ) (17 ) 6,872 3,057 (3,078 ) (517 ) (411 ) (50 ) (999 ) 194 (194 ) - (334 ) (334 ) 151 (151 ) - 9,462 2,184 3,078 194 160 600 411 119 73 - 16,281 1,521 304 697 43 33 163 14 23 16 47 2,861 7,941 1,880 2,381 151 127 437 397 96 57 (47 ) 13,420 Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com